[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-eosinophilic-acos-asthma-copd-overlap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-eosinophilic-acos-asthma-copd-overlap":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100640219","blood-exosomal-multi-omics-and-lung-radiomics-for-predicting-efficacy-and-prognosis-of-severe-eosinophilic-acos-with-biologics-100640219",false,"NCT07602881","Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics","Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS (Asthma-COPD Overlap Syndrome) Treated With Different Biologics: A Real-World Observational Study","ACOS","Inclusion Criteria:\n\n* Age ≥ 14 years\n* Clinician decision to start biologic (benralizumab, mepolizumab, or dupilumab) for severe eosinophilic ACOS\n* Blood eosinophils ≥150\u002FμL within 3 months prior to informed consent, or ≥300\u002FμL within 1 year prior\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Currently participating in any other interventional clinical trial\n* Known allergy or hypersensitivity to any component of the study drugs\n* Any type of malignancy\n* Prior or current biologic treatment for ACOS","ALL","14 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap) patients treated with different biologics (benralizumab, mepolizumab, dupilumab). Then, to prospectively follow patients for 48 weeks after biologic initiation and collect clinical data, blood samples, and imaging features. Finally, to build a multi-dimensional predictive model for efficacy and prognosis of severe eosinophilic ACOS.",[25],"Severe Eosinophilic ACOS (Asthma-COPD Overlap)",[27,28,29,30,31],"Biomarker","Exosomal Multi-omics","Radiomics","Biologics","Severe Eosinophilic ACOS","NOT_YET_RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-22","ACTUAL",{"date":38,"type":21},"2026-06-01",{"date":40,"type":21},"2028-07-01",{"name":42,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER"]